Survodutide for Obesity and MASH/NASH — Weight & Metabolism
Investigational dual GLP-1/glucagon receptor agonist showing exceptional weight loss and liver fat reduction in Phase 2/3 trials.
Overview
Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma, currently in Phase 3 clinical trials for obesity and MASH (metabolic dysfunction-associated steatohepatitis). Phase 2 trial data (n=387, 46 weeks) demonstrated up to 18.7% body weight loss at the highest dose (6.0mg weekly) vs 2.1% with placebo, with 83% of patients achieving >=5% weight loss and 57% achieving >=15% weight loss. In the Phase 2b MASH trial, survodutide achieved 83% histological MASH resolution (vs 18.2% placebo) and liver fat reduction of 70-80% measured by MRI-PDFF. The dual agonism provides additive metabolic benefits: GLP-1 receptor activation suppresses appetite while glucagon receptor activation enhances hepatic fat oxidation and energy expenditure. Phase 3 trials (SYNCHRONIZE program) are ongoing for both obesity and MASH indications. PMID: 37840095, 38587242.
Indications
- Obesity (BMI >=30) or overweight (BMI >=27) with metabolic comorbidities (Phase 3)
- MASH/NASH with liver fibrosis (Phase 3)
- Patients with obesity complicated by non-alcoholic fatty liver disease
- Metabolic syndrome with hepatic steatosis requiring both weight and liver fat reduction
Mechanism of Action
Excess caloric intake drives adiposity, hepatic steatosis, and MASH progression with fibrosis risk
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Survodutide | 0.6 mg -> 2.4 mg | Once weekly, escalate every 4 weeks | Gradual titration: 0.6 -> 1.2 -> 1.8 -> 2.4mg to minimize GI side effects |
| Survodutide | 2.4 mg | Once weekly | Lower maintenance dose; ~14% weight loss at 46 weeks in Phase 2 |
| Survodutide | 4.8 mg | Once weekly | Higher maintenance dose; up to 18.7% weight loss and maximum liver fat reduction |
Evidence Grade
GRADE C
Safety & Contraindications
- Investigational compound - NOT FDA-approved; available only through clinical trials
- GI side effects are the most common adverse events: nausea (42%), diarrhea (24%), vomiting (20%)
- Dose-dependent GI tolerability; extended titration schedule reduces discontinuation rates
- Glucagon receptor activation may transiently increase hepatic glucose output - monitor blood glucose
- Discontinuation rates due to adverse events: 5-15% across dose groups in Phase 2
- Long-term safety data (>1 year) not yet available; ongoing Phase 3 trials will establish safety profile